Article

AAX Biotech has received an investment from Trio Impact Invest AB to support the development and scaling of its antibody technology platforms. This funding will facilitate expanded applications and strengthen industry collaborations, including a partnership with Daiichi Sankyo. The investment reflects AAX Biotech's recent technological and commercial advancements.